- Home
- RIGL vs THW Comparison
RIGL vs THW Comparison
Compare RIGL & THW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- THW
- Stock Information
- Founded
- RIGL 1996
- THW 2015
- Country
- RIGL United States
- THW United States
- Employees
- RIGL N/A
- THW N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- THW Finance Companies
- Sector
- RIGL Health Care
- THW Finance
- Exchange
- RIGL Nasdaq
- THW Nasdaq
- Market Cap
- RIGL 335.5M
- THW 391.1M
- IPO Year
- RIGL 2000
- THW N/A
- Fundamental
- Price
- RIGL $20.97
- THW $10.44
- Analyst Decision
- RIGL Buy
- THW
- Analyst Count
- RIGL 5
- THW 0
- Target Price
- RIGL $36.40
- THW N/A
- AVG Volume (30 Days)
- RIGL 217.1K
- THW 149.9K
- Earning Date
- RIGL 08-05-2025
- THW 01-01-0001
- Dividend Yield
- RIGL N/A
- THW 10.76%
- EPS Growth
- RIGL N/A
- THW N/A
- EPS
- RIGL 2.08
- THW N/A
- Revenue
- RIGL $203,077,000.00
- THW N/A
- Revenue This Year
- RIGL $14.41
- THW N/A
- Revenue Next Year
- RIGL $15.97
- THW N/A
- P/E Ratio
- RIGL $10.14
- THW N/A
- Revenue Growth
- RIGL 70.16
- THW N/A
- 52 Week Low
- RIGL $7.48
- THW $9.76
- 52 Week High
- RIGL $29.82
- THW $14.89
- Technical
- Relative Strength Index (RSI)
- RIGL 61.71
- THW 48.66
- Support Level
- RIGL $18.63
- THW $10.10
- Resistance Level
- RIGL $20.99
- THW $10.51
- Average True Range (ATR)
- RIGL 1.07
- THW 0.15
- MACD
- RIGL 0.11
- THW 0.03
- Stochastic Oscillator
- RIGL 82.81
- THW 56.67
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About THW abrdn World Healthcare Fund Shares of Beneficial Interest
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies engaged in the healthcare industry. The company's investment portfolio comprises investments in different sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other areas. It also male into REIT Real Estate.